Clinical Parameters of Metastatic Melanoma Patients
| Patient* . | . | Age . | . | Tumor stage (AJCC) . | . | LN dissection . | . | Disease interval‡ . | . | Previous treatment . | . | Survival status 1998 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| yr | yr | yr | ||||||||||
| LAU 50 | 65 | pT4aN2cM0 | 1 N+/14 N | 5 | ILP (TIM) | 8, tumor free | ||||||
| LAU 56 | 39 | pT4aN2cM0 | 2 N+/17 N | 10 | ILP (TIM) | 11, tumor free | ||||||
| LAU 132 | 35 | pT3aN2aM0 | 15 N+/16 N | 1.3 | ILP (M) IFN-α, 1 yr§ | 3, tumor free | ||||||
| LAU 181 | 42 | pT4N2M0 | 2 N+/14 N | 2 | Surgery | 3, tumor free | ||||||
| LAU 203 | 66 | pTxN2cM0 | ≥3 N+ | 5 | Surgery | 7, tumor free | ||||||
| LAU 233 | 75 | pT4N2cM0 | 6 N+/10 N | 2 | None | 4, tumor free | ||||||
| LAU 240 | 65 | pTxN2cM0 | 11 N+/15 N | <1 | None | 1, PD | ||||||
| LAU 253 | 61 | pT3aN2M0 | 18 N+/27 N | 1.3 | Surgery | 4, PD | ||||||
| LAU 267 | 45 | pT4aN2cM0 | 1 N+ | <1 | IFN-α, <1 yr | 1, PD |
| Patient* . | . | Age . | . | Tumor stage (AJCC) . | . | LN dissection . | . | Disease interval‡ . | . | Previous treatment . | . | Survival status 1998 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| yr | yr | yr | ||||||||||
| LAU 50 | 65 | pT4aN2cM0 | 1 N+/14 N | 5 | ILP (TIM) | 8, tumor free | ||||||
| LAU 56 | 39 | pT4aN2cM0 | 2 N+/17 N | 10 | ILP (TIM) | 11, tumor free | ||||||
| LAU 132 | 35 | pT3aN2aM0 | 15 N+/16 N | 1.3 | ILP (M) IFN-α, 1 yr§ | 3, tumor free | ||||||
| LAU 181 | 42 | pT4N2M0 | 2 N+/14 N | 2 | Surgery | 3, tumor free | ||||||
| LAU 203 | 66 | pTxN2cM0 | ≥3 N+ | 5 | Surgery | 7, tumor free | ||||||
| LAU 233 | 75 | pT4N2cM0 | 6 N+/10 N | 2 | None | 4, tumor free | ||||||
| LAU 240 | 65 | pTxN2cM0 | 11 N+/15 N | <1 | None | 1, PD | ||||||
| LAU 253 | 61 | pT3aN2M0 | 18 N+/27 N | 1.3 | Surgery | 4, PD | ||||||
| LAU 267 | 45 | pT4aN2cM0 | 1 N+ | <1 | IFN-α, <1 yr | 1, PD |
AJCC, American Joint Committee on Cancer. ILP (TIM), Isolated limb perfusion with TNF-α (4 mg), IFN-γ (0.2 mg), and melphalan. ILP (M), Isolated limb perfusion with melphalan alone. N, Node. PD, Progressive disease.
All metastatic nodes included in this series, except that from LAU 56, were found to express Melan-A and tyrosinase mRNA by RT-PCR.
Time elapsed between diagnosis of primary melanoma and surgical resection of LNs analyzed in this study.
IFN-α administered as adjuvant therapy intermediate high dose regimen.